The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphismsNOURSE, Jamie P; LEA, Rod; CROOKS, Pauline et al.Blood coagulation & fibrinolysis. 2012, Vol 23, Num 1, pp 45-50, issn 0957-5235, 6 p.Article

Effect of FCGR2A and FCGR3A variants on CLL outcomeDORNAN, David; SPLEISS, Olivia; WARZOCHA, Krzysztof et al.Blood. 2010, Vol 116, Num 20, pp 4212-4222, issn 0006-4971, 11 p.Article

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphismsGHESQUIERES, Hervé; CARTRON, Guillaume; DUPUIS, Jehan et al.Blood. 2012, Vol 120, Num 13, pp 2650-2657, issn 0006-4971, 8 p.Article

A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignanciesTAKAMI, A; ESPINOZA, J. L; INOUE, M et al.Bone marrow transplantation (Basingstoke). 2011, Vol 46, Num 2, pp 238-243, issn 0268-3369, 6 p.Article

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaTREON, Steven P; GUANG YANG; PATTERSON, Christopher J et al.British journal of haematology. 2011, Vol 154, Num 2, pp 223-228, issn 0007-1048, 6 p.Article

Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical applicationLEE, Soo-Youn; MCLEOD, Howard L.Journal of pathology (Print). 2011, Vol 223, Num 1, pp 15-27, issn 0022-3417, 13 p.Article

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trialROCA, Lise; DIERAS, Véronique; MARTIN, Anne-Laure et al.Breast cancer research and treatment. 2013, Vol 139, Num 3, pp 789-800, issn 0167-6806, 12 p.Article

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximabWU ZHANG; GORDON, Michael; IQBAL, Syma et al.Journal of clinical oncology. 2007, Vol 25, Num 24, pp 3712-3718, issn 0732-183X, 7 p.Article

Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopeniaCOOPER, Nichola; STASI, Roberto; CUNNINGHAM-RUNDLES, Susanna et al.British journal of haematology. 2012, Vol 158, Num 4, pp 539-547, issn 0007-1048, 9 p.Article

Genetic profiling of GSTP1, DPYD, FCGR2A, FCGR3A and CCND1 genes in an Argentinian populationGALVAN, Cristian A; ELBARCHA, Osvaldo C; FERNANDEZ, Eduardo J et al.Clinical biochemistry. 2011, Vol 44, Num 13, pp 1058-1061, issn 0009-9120, 4 p.Article

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancerPANDER, Jan; GELDERBLOM, Hans; ANTONINI, Ninja F et al.European journal of cancer (1990). 2010, Vol 46, Num 10, pp 1829-1834, issn 0959-8049, 6 p.Article

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemiaLIN, Thomas S; FLINN, Ian W; MODALI, Rama et al.Blood. 2005, Vol 105, Num 1, pp 289-291, issn 0006-4971, 3 p.Article